Dobutamine Infusion
Syringe pump continuous infusion preparation (5,000 mcg/mL), inotropic titration, and hemodynamic surveillance protocol.
Syringe Pump Infusion Preparation (Standard Concentration)
| Ampoule Presentation | 250 mg per 5 mL ampoule |
|---|---|
| Dobutamine Dose | 250 mg (5 mL = one 5 mL ampoule) |
| Compatible Diluent | 45 mL of D5W or 0.9% Sodium Chloride (NS) |
| Final Syringe Volume | 50 mL |
| Final Concentration | 5,000 mcg/mL (5 mg/mL) |
| Stability | 24 hours at room temperature |
Materials Required
- Dobutamine ampoule 250 mg/5 mL × 1
- 60 mL Luer-lock syringe
- 0.9% Sodium Chloride (NS) or 5% Dextrose (D5W)
- Sterile drawing-up needle / filter needle
- Dedicated syringe pump infusion label
- Extension line (100 cm)
- Alcohol chlorhexidine swabs
Preparation Procedure (Aseptic Non-Touch Technique)
- Verification: Verify the written physician order, patient identity, body weight, and clinical indication.
- Hand Hygiene: Perform thorough hand hygiene and clean preparation workspace.
- Ampoule Check: Check the dobutamine ampoule for:
- Correct drug and strength, dobutamine hydrochloride (50 mg/mL)
- Expiry date
- Container integrity, clarity, and absence of precipitate
- Withdrawal: Open one ampoule of dobutamine. Withdraw 5 mL into a 60 mL Luer-lock syringe (Total dobutamine drawn: 5 mL = 250 mg dobutamine).
- Dilution: Add 45 mL of 0.9% Sodium Chloride or D5W to a final volume of 50 mL.
- Mixing: Gently invert the syringe several times to ensure uniform mixing.
- Visual Inspection: Inspect solution to ensure it is clear and free of visible particles. A faint pink tint may develop from mild oxidation without significant loss of potency; discard if cloudy, precipitated, or markedly discoloured.
- Labeling & Dual Verification: Apply infusion label and obtain an independent double-check by another registered nurse.
- Syringe Pump Setup: Prime the extension set and install into the syringe pump.
🔒 Lumen Policy: Dobutamine is inactivated in alkaline solutions (sodium bicarbonate) and is incompatible with numerous medications, including heparin, furosemide, and aminophylline. Infuse via a dedicated lumen, preferably central.
⚠️ Peripheral Administration: Dobutamine may be infused through a large, well-secured peripheral vein when central access is unavailable, with regular site checks for infiltration.
Administration & Titration
Recommended Dosing Parameters
- Administration Route: Administer via syringe pump; dedicated lumen preferred.
- Recommended Starting Dose: 2.5 mcg/kg/min (titrate infusion to achieve desired hemodynamic result).
- Titration Step: Increase by 2.5 mcg/kg/min every 10 to 30 minutes according to response.
- Typical ICU Titration Range: 2.5 to 10 mcg/kg/min.
- Maximum Dose: 20 mcg/kg/min. Higher doses only under direct intensivist supervision.
- Hypovolemia: Correct intravascular volume depletion before initiation.
- Weaning: Reduce gradually while monitoring cardiac output and perfusion markers.
- Syringe Continuity: Do not allow the infusion to run out. A syringe can be made up to a maximum of 1 hour in advance and labelled clearly with contents and expiry.
- Discard Policy: Discard 24 hours after preparation or earlier if the solution becomes cloudy, precipitated, or contaminated.
Hemodynamic Monitoring Requirements
- Monitor arterial blood pressure continuously (invasive arterial line preferred).
- Monitor heart rate and continuous ECG rhythm for sinus tachycardia, atrial fibrillation, and ventricular ectopy.
- Observe for chest pain or ECG changes suggesting myocardial ischemia.
- Track cardiac output indices where available (echocardiography, ScvO2, cardiac output monitoring).
- Assess end-organ perfusion markers (urine output, mental status, capillary refill, serum lactate).
- Check serum potassium periodically; β-agonism can lower potassium.
Clinical Cautions
- Atrial Fibrillation: Enhances AV conduction and can produce a rapid ventricular response.
- β-Blockers: Blunt the inotropic response; higher doses may be required.
- Prolonged Infusion: Tolerance may develop after about 72 hours.
- Contraindicated: Hypertrophic obstructive cardiomyopathy (dynamic LVOT obstruction) and known hypersensitivity, including to sulfite-containing formulations.
Infusion Site Surveillance & Response Protocol
Dobutamine is a weaker vasoconstrictor than vasopressors, but extravasation can still cause local irritation, inflammation, and tissue injury.
Normal Infusion Site
- No cutaneous blanching or erythema
- No local swelling
- No pain, burning, or stinging
- No tissue discolouration
Extravasation Suspected:
- STOP infusion immediately (do not flush line).
- Notify clinician promptly and arrange alternative access so the infusion is not interrupted for long.
- Aspirate residual drug through the cannula if possible, then remove catheter.
- Document event in patient clinical record.
Dobutamine Infusion Rate Chart (5,000 mcg/mL)
Shows equivalent dose in mcg/kg/min for a given pump rate (mL/hr) across patient weights. Dedicated lumen administration preferred.
| Rate (mL/hr) |
Weight (Kg) and Dose (mcg/kg/min) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40 kg | 45 kg | 50 kg | 55 kg | 60 kg | 65 kg | 70 kg | 75 kg | 80 kg | 85 kg | 90 kg | 95 kg | 100 kg | |
| 1 | 2.1 | 1.9 | 1.7 | 1.5 | 1.4 | 1.3 | 1.2 | 1.1 | 1.0 | 1.0 | 0.9 | 0.9 | 0.8 |
| 2 | 4.2 | 3.7 | 3.3 | 3.0 | 2.8 | 2.6 | 2.4 | 2.2 | 2.1 | 2.0 | 1.9 | 1.8 | 1.7 |
| 3 | 6.2 | 5.6 | 5.0 | 4.5 | 4.2 | 3.8 | 3.6 | 3.3 | 3.1 | 2.9 | 2.8 | 2.6 | 2.5 |
| 4 | 8.3 | 7.4 | 6.7 | 6.1 | 5.6 | 5.1 | 4.8 | 4.4 | 4.2 | 3.9 | 3.7 | 3.5 | 3.3 |
| 5 | 10.4 | 9.3 | 8.3 | 7.6 | 6.9 | 6.4 | 6.0 | 5.6 | 5.2 | 4.9 | 4.6 | 4.4 | 4.2 |
| 6 | 12.5 | 11.1 | 10.0 | 9.1 | 8.3 | 7.7 | 7.1 | 6.7 | 6.2 | 5.9 | 5.6 | 5.3 | 5.0 |
| 7 | 14.6 | 13.0 | 11.7 | 10.6 | 9.7 | 9.0 | 8.3 | 7.8 | 7.3 | 6.9 | 6.5 | 6.1 | 5.8 |
| 8 | 16.7 | 14.8 | 13.3 | 12.1 | 11.1 | 10.3 | 9.5 | 8.9 | 8.3 | 7.8 | 7.4 | 7.0 | 6.7 |
| 9 | 18.8 | 16.7 | 15.0 | 13.6 | 12.5 | 11.5 | 10.7 | 10.0 | 9.4 | 8.8 | 8.3 | 7.9 | 7.5 |
| 10 | 20.8 | 18.5 | 16.7 | 15.2 | 13.9 | 12.8 | 11.9 | 11.1 | 10.4 | 9.8 | 9.3 | 8.8 | 8.3 |
| 11 | 22.9 | 20.4 | 18.3 | 16.7 | 15.3 | 14.1 | 13.1 | 12.2 | 11.5 | 10.8 | 10.2 | 9.6 | 9.2 |
| 12 | 25.0 | 22.2 | 20.0 | 18.2 | 16.7 | 15.4 | 14.3 | 13.3 | 12.5 | 11.8 | 11.1 | 10.5 | 10.0 |
| 13 | 27.1 | 24.1 | 21.7 | 19.7 | 18.1 | 16.7 | 15.5 | 14.4 | 13.5 | 12.7 | 12.0 | 11.4 | 10.8 |
| 14 | 29.2 | 25.9 | 23.3 | 21.2 | 19.4 | 17.9 | 16.7 | 15.6 | 14.6 | 13.7 | 13.0 | 12.3 | 11.7 |
| 15 | 31.2 | 27.8 | 25.0 | 22.7 | 20.8 | 19.2 | 17.9 | 16.7 | 15.6 | 14.7 | 13.9 | 13.2 | 12.5 |
| 16 | 33.3 | 29.6 | 26.7 | 24.2 | 22.2 | 20.5 | 19.0 | 17.8 | 16.7 | 15.7 | 14.8 | 14.0 | 13.3 |
| 17 | 35.4 | 31.5 | 28.3 | 25.8 | 23.6 | 21.8 | 20.2 | 18.9 | 17.7 | 16.7 | 15.7 | 14.9 | 14.2 |
| 18 | 37.5 | 33.3 | 30.0 | 27.3 | 25.0 | 23.1 | 21.4 | 20.0 | 18.8 | 17.6 | 16.7 | 15.8 | 15.0 |
| 19 | 39.6 | 35.2 | 31.7 | 28.8 | 26.4 | 24.4 | 22.6 | 21.1 | 19.8 | 18.6 | 17.6 | 16.7 | 15.8 |
| 20 | 41.7 | 37.0 | 33.3 | 30.3 | 27.8 | 25.6 | 23.8 | 22.2 | 20.8 | 19.6 | 18.5 | 17.5 | 16.7 |
| 21 | 43.8 | 38.9 | 35.0 | 31.8 | 29.2 | 26.9 | 25.0 | 23.3 | 21.9 | 20.6 | 19.4 | 18.4 | 17.5 |
| 22 | 45.8 | 40.7 | 36.7 | 33.3 | 30.6 | 28.2 | 26.2 | 24.4 | 22.9 | 21.6 | 20.4 | 19.3 | 18.3 |
| 23 | 47.9 | 42.6 | 38.3 | 34.8 | 31.9 | 29.5 | 27.4 | 25.6 | 24.0 | 22.5 | 21.3 | 20.2 | 19.2 |
| 24 | 50.0 | 44.4 | 40.0 | 36.4 | 33.3 | 30.8 | 28.6 | 26.7 | 25.0 | 23.5 | 22.2 | 21.1 | 20.0 |
Infusion Conversion (Solution Concentration 5,000 mcg/mL)
Standard equations for a 5,000 mcg/mL solution (250 mg in 50 mL):
Rate (mL/hr) = [ Dose (mcg/kg/min) × Weight (kg) × 60 ] / 5000
Shortcut: Rate = Dose × Weight × 0.012
Dose (mcg/kg/min) = [ Rate (mL/hour) × Concentration (5000 mcg/mL) ] / [ Weight (kg) × 60 ]
'Shortcut' example: 70 kg patient at 5 mcg/kg/min → 5 × 70 × 0.012 = 4.2 mL/hr.